Unknown

Dataset Information

0

Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT.


ABSTRACT: BACKGROUND:To evaluate the effect of upadacitinib on patient-reported outcomes (PROs) in patients with RA who had an inadequate response to csDMARDs. METHODS:Patients in SELECT-NEXT, a randomised controlled trial, were on a background of csDMARDs and received upadacitinib 15?mg and 30?mg or placebo daily for 12?weeks. PROs included Patient Global Assessment of Disease Activity (PtGA), pain, Health Assessment Questionnaire-Disability Index (HAQ-DI), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), duration and severity of morning (AM) joint stiffness, Short Form 36 Health Survey (SF-36), and Work Instability Scale for RA (RA-WIS). Least squares mean (LSM) changes were based on mixed-effect repeated measure models. Percentages of patients reporting improvements ? minimum clinically important differences (MCIDs) and scores ? normative values and number needed to treat (NNT) were determined; group comparisons used chi-square tests. RESULTS:Data from 661 patients were analysed. Compared with placebo, patients receiving upadacitinib reported statistically significant improvements (both doses, P?

SUBMITTER: Strand V 

PROVIDER: S-EPMC6902348 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT.

Strand Vibeke V   Pope Janet J   Tundia Namita N   Friedman Alan A   Camp Heidi S HS   Pangan Aileen A   Ganguli Arijit A   Fuldeore Mahesh M   Goldschmidt Debbie D   Schiff Michael M  

Arthritis research & therapy 20191209 1


<h4>Background</h4>To evaluate the effect of upadacitinib on patient-reported outcomes (PROs) in patients with RA who had an inadequate response to csDMARDs.<h4>Methods</h4>Patients in SELECT-NEXT, a randomised controlled trial, were on a background of csDMARDs and received upadacitinib 15 mg and 30 mg or placebo daily for 12 weeks. PROs included Patient Global Assessment of Disease Activity (PtGA), pain, Health Assessment Questionnaire-Disability Index (HAQ-DI), Functional Assessment of Chronic  ...[more]

Similar Datasets

| S-EPMC6889334 | biostudies-literature
| S-EPMC4941182 | biostudies-literature
| S-EPMC8572272 | biostudies-literature
| S-EPMC5817244 | biostudies-literature
| S-EPMC9229430 | biostudies-literature
| S-EPMC7569379 | biostudies-literature
| S-EPMC10377185 | biostudies-literature
| S-EPMC8516509 | biostudies-literature
| S-EPMC6824456 | biostudies-literature
| S-EPMC6824353 | biostudies-literature